[{"id":"d12325fc-0a21-4937-8ffe-ebfd224dc25b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03236974","created_at":"2021-01-18T15:59:45.433Z","updated_at":"2024-07-02T16:36:50.392Z","phase":"Phase 1","brief_title":"Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.","source_id_and_acronym":"NCT03236974","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER expression • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • AZD9496"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 10/05/2017","start_date":" 10/05/2017","primary_txt":" Primary completion: 02/12/2019","primary_completion_date":" 02/12/2019","study_txt":" Completion: 02/12/2019","study_completion_date":" 02/12/2019","last_update_posted":"2020-02-06"},{"id":"787fbf0f-4e7e-42d9-ad2c-ce143ab28da3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02248090","created_at":"2021-01-18T10:33:05.301Z","updated_at":"2024-07-02T16:36:58.681Z","phase":"Phase 1","brief_title":"AZD9496 First Time in Patients Ascending Dose Study","source_id_and_acronym":"NCT02248090","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD9496"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 10/22/2014","start_date":" 10/22/2014","primary_txt":" Primary completion: 01/31/2017","primary_completion_date":" 01/31/2017","study_txt":" Completion: 04/03/2019","study_completion_date":" 04/03/2019","last_update_posted":"2019-06-24"}]